JP2018512891A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512891A5 JP2018512891A5 JP2018503698A JP2018503698A JP2018512891A5 JP 2018512891 A5 JP2018512891 A5 JP 2018512891A5 JP 2018503698 A JP2018503698 A JP 2018503698A JP 2018503698 A JP2018503698 A JP 2018503698A JP 2018512891 A5 JP2018512891 A5 JP 2018512891A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- cell
- composition
- based shuttle
- shuttle agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 39
- 102000004196 processed proteins & peptides Human genes 0.000 claims 33
- 229920001184 polypeptide Polymers 0.000 claims 31
- 239000000203 mixture Substances 0.000 claims 25
- 239000003795 chemical substances by application Substances 0.000 claims 18
- 210000003527 eukaryotic cell Anatomy 0.000 claims 16
- 230000026683 transduction Effects 0.000 claims 10
- 238000010361 transduction Methods 0.000 claims 10
- 108091033409 CRISPR Proteins 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 9
- 210000000172 cytosol Anatomy 0.000 claims 9
- -1 PTD4 Proteins 0.000 claims 8
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 6
- 230000035699 permeability Effects 0.000 claims 5
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 230000002101 lytic effect Effects 0.000 claims 3
- 241000670727 Amida Species 0.000 claims 2
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims 2
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims 2
- 102100031780 Endonuclease Human genes 0.000 claims 2
- 108010042407 Endonucleases Proteins 0.000 claims 2
- 101710154606 Hemagglutinin Proteins 0.000 claims 2
- 108010036176 Melitten Proteins 0.000 claims 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims 2
- 241000737052 Naso hexacanthus Species 0.000 claims 2
- 102000007999 Nuclear Proteins Human genes 0.000 claims 2
- 108010089610 Nuclear Proteins Proteins 0.000 claims 2
- 101710163270 Nuclease Proteins 0.000 claims 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims 2
- 101710176177 Protein A56 Proteins 0.000 claims 2
- 101150106167 SOX9 gene Proteins 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 238000010459 TALEN Methods 0.000 claims 2
- 108091023040 Transcription factor Proteins 0.000 claims 2
- 102000040945 Transcription factor Human genes 0.000 claims 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 210000004443 dendritic cell Anatomy 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 239000000185 hemagglutinin Substances 0.000 claims 2
- 210000002865 immune cell Anatomy 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 claims 2
- 230000002438 mitochondrial effect Effects 0.000 claims 2
- 108010043655 penetratin Proteins 0.000 claims 2
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 claims 2
- 230000000858 peroxisomal effect Effects 0.000 claims 2
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- IEXIHWCBQMQDHC-KEIUHOJNSA-N 5,9-hexacosadienoic acid Chemical compound CCCCCCCCCCCCCCCC\C=C\CC\C=C\CCCC(O)=O IEXIHWCBQMQDHC-KEIUHOJNSA-N 0.000 claims 1
- 102100027452 ATP-dependent DNA helicase Q4 Human genes 0.000 claims 1
- 108700031308 Antennapedia Homeodomain Proteins 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims 1
- 238000010354 CRISPR gene editing Methods 0.000 claims 1
- 101100189913 Caenorhabditis elegans pept-1 gene Proteins 0.000 claims 1
- 108010078791 Carrier Proteins Proteins 0.000 claims 1
- 101800003223 Cecropin-A Proteins 0.000 claims 1
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 claims 1
- 108050008072 Cytochrome c oxidase subunit IV Proteins 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 101100129232 Danio rerio mafaa gene Proteins 0.000 claims 1
- 102000016607 Diphtheria Toxin Human genes 0.000 claims 1
- 108010053187 Diphtheria Toxin Proteins 0.000 claims 1
- 101100206886 Drosophila melanogaster Tim9a gene Proteins 0.000 claims 1
- 101150099612 Esrrb gene Proteins 0.000 claims 1
- 102100035421 Forkhead box protein O3 Human genes 0.000 claims 1
- 101150032426 HLF gene Proteins 0.000 claims 1
- 108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 claims 1
- 102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 claims 1
- 108010033040 Histones Proteins 0.000 claims 1
- 102100028404 Homeobox protein Hox-B4 Human genes 0.000 claims 1
- 101000580577 Homo sapiens ATP-dependent DNA helicase Q4 Proteins 0.000 claims 1
- 101000877681 Homo sapiens Forkhead box protein O3 Proteins 0.000 claims 1
- 101000839788 Homo sapiens Homeobox protein Hox-B4 Proteins 0.000 claims 1
- 101001053263 Homo sapiens Insulin gene enhancer protein ISL-1 Proteins 0.000 claims 1
- 101000740178 Homo sapiens Sal-like protein 4 Proteins 0.000 claims 1
- 101000713602 Homo sapiens T-box transcription factor TBX21 Proteins 0.000 claims 1
- 101000711846 Homo sapiens Transcription factor SOX-9 Proteins 0.000 claims 1
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 claims 1
- 108050009527 Hypoxia-inducible factor-1 alpha Proteins 0.000 claims 1
- 102100024392 Insulin gene enhancer protein ISL-1 Human genes 0.000 claims 1
- 101150051019 Klrg1 gene Proteins 0.000 claims 1
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 claims 1
- 102100022699 Lymphoid enhancer-binding factor 1 Human genes 0.000 claims 1
- 108090001093 Lymphoid enhancer-binding factor 1 Proteins 0.000 claims 1
- 101150084866 MAFA gene Proteins 0.000 claims 1
- 101100381525 Mus musculus Bcl6 gene Proteins 0.000 claims 1
- 101100445364 Mus musculus Eomes gene Proteins 0.000 claims 1
- 101000687343 Mus musculus PR domain zinc finger protein 1 Proteins 0.000 claims 1
- 101100189471 Mus musculus Pbx1 gene Proteins 0.000 claims 1
- 101100078259 Mus musculus Runx1t1 gene Proteins 0.000 claims 1
- 102000002488 Nucleoplasmin Human genes 0.000 claims 1
- 108010062618 Oncogene Proteins v-rel Proteins 0.000 claims 1
- 102100041030 Pancreas/duodenum homeobox protein 1 Human genes 0.000 claims 1
- 101710144033 Pancreas/duodenum homeobox protein 1 Proteins 0.000 claims 1
- 108010088535 Pep-1 peptide Proteins 0.000 claims 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims 1
- 101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 claims 1
- 241000589516 Pseudomonas Species 0.000 claims 1
- 101710183548 Pyridoxal 5'-phosphate synthase subunit PdxS Proteins 0.000 claims 1
- 102100033975 Ran-binding protein 3 Human genes 0.000 claims 1
- 101710176056 Ran-binding protein 3 Proteins 0.000 claims 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 claims 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 1
- 101150086694 SLC22A3 gene Proteins 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 101100465559 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PRE7 gene Proteins 0.000 claims 1
- 102100037192 Sal-like protein 4 Human genes 0.000 claims 1
- 108010002687 Survivin Proteins 0.000 claims 1
- 102100036840 T-box transcription factor TBX21 Human genes 0.000 claims 1
- 101150023892 TIMM9 gene Proteins 0.000 claims 1
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 claims 1
- 102100034204 Transcription factor SOX-9 Human genes 0.000 claims 1
- 241000269370 Xenopus <genus> Species 0.000 claims 1
- 101100445365 Xenopus laevis eomes gene Proteins 0.000 claims 1
- 101001062349 Xenopus tropicalis Forkhead box protein A1 Proteins 0.000 claims 1
- 101150053182 Zfp37 gene Proteins 0.000 claims 1
- 102100023552 Zinc finger protein 37 homolog Human genes 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000004102 animal cell Anatomy 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- HCQPHKMLKXOJSR-IRCPFGJUSA-N cecropin-a Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(N)=O)[C@@H](C)CC)C(C)C)[C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CCCCN)C1=CC=CC=C1 HCQPHKMLKXOJSR-IRCPFGJUSA-N 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000001723 extracellular space Anatomy 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 101150111214 lin-28 gene Proteins 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 108060005597 nucleoplasmin Proteins 0.000 claims 1
- 101150076896 pts1 gene Proteins 0.000 claims 1
- 230000001172 regenerating effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- GUGNSJAORJLKGP-UHFFFAOYSA-K sodium 8-methoxypyrene-1,3,6-trisulfonate Chemical compound [Na+].[Na+].[Na+].C1=C2C(OC)=CC(S([O-])(=O)=O)=C(C=C3)C2=C2C3=C(S([O-])(=O)=O)C=C(S([O-])(=O)=O)C2=C1 GUGNSJAORJLKGP-UHFFFAOYSA-K 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021092230A JP2021121224A (ja) | 2015-04-10 | 2021-06-01 | 標的真核細胞のサイトゾルへのポリペプチドカーゴの形質導入効率を改善するためのポリペプチドベースのシャトル剤、その使用、それと関連する方法及びキット |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562145760P | 2015-04-10 | 2015-04-10 | |
| US62/145,760 | 2015-04-10 | ||
| US201562246892P | 2015-10-27 | 2015-10-27 | |
| US62/246,892 | 2015-10-27 | ||
| PCT/CA2016/050403 WO2016161516A1 (en) | 2015-04-10 | 2016-04-08 | Polypeptide-based shuttle agents for improving the transduction efficiency of polypeptide cargos to the cytosol of target eukaryotic cells, uses thereof, methods and kits relating to same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021092230A Division JP2021121224A (ja) | 2015-04-10 | 2021-06-01 | 標的真核細胞のサイトゾルへのポリペプチドカーゴの形質導入効率を改善するためのポリペプチドベースのシャトル剤、その使用、それと関連する方法及びキット |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512891A JP2018512891A (ja) | 2018-05-24 |
| JP2018512891A5 true JP2018512891A5 (enExample) | 2019-05-16 |
| JP6956705B2 JP6956705B2 (ja) | 2021-11-02 |
Family
ID=57071637
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018503698A Active JP6956705B2 (ja) | 2015-04-10 | 2016-04-08 | 標的真核細胞のサイトゾルへのポリペプチドカーゴの形質導入効率を改善するためのポリペプチドベースのシャトル剤、その使用、それと関連する方法及びキット |
| JP2021092230A Pending JP2021121224A (ja) | 2015-04-10 | 2021-06-01 | 標的真核細胞のサイトゾルへのポリペプチドカーゴの形質導入効率を改善するためのポリペプチドベースのシャトル剤、その使用、それと関連する方法及びキット |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021092230A Pending JP2021121224A (ja) | 2015-04-10 | 2021-06-01 | 標的真核細胞のサイトゾルへのポリペプチドカーゴの形質導入効率を改善するためのポリペプチドベースのシャトル剤、その使用、それと関連する方法及びキット |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9738687B2 (enExample) |
| EP (1) | EP3280739B1 (enExample) |
| JP (2) | JP6956705B2 (enExample) |
| KR (2) | KR102697262B1 (enExample) |
| CN (1) | CN107636017B (enExample) |
| AU (1) | AU2016245347B2 (enExample) |
| CA (2) | CA2981716C (enExample) |
| ES (1) | ES2864758T3 (enExample) |
| IL (1) | IL254919B (enExample) |
| SG (1) | SG11201708336YA (enExample) |
| WO (1) | WO2016161516A1 (enExample) |
Families Citing this family (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016245347B2 (en) * | 2015-04-10 | 2021-01-28 | Feldan Bio Inc. | Polypeptide-based shuttle agents for improving the transduction efficiency of polypeptide cargos to the cytosol of target eukaryotic cells, uses thereof, methods and kits relating to same |
| US11208649B2 (en) | 2015-12-07 | 2021-12-28 | Zymergen Inc. | HTP genomic engineering platform |
| US9988624B2 (en) | 2015-12-07 | 2018-06-05 | Zymergen Inc. | Microbial strain improvement by a HTP genomic engineering platform |
| KR20180084756A (ko) | 2015-12-07 | 2018-07-25 | 지머젠 인코포레이티드 | 코리네박테리움 글루타미컴으로부터의 프로모터 |
| WO2017175072A1 (en) * | 2016-04-08 | 2017-10-12 | Feldan Bio Inc. | Peptide shuttle based gene disruption |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| WO2017207589A1 (en) | 2016-06-01 | 2017-12-07 | Kws Saat Se | Hybrid nucleic acid sequences for genome engineering |
| WO2018005793A1 (en) | 2016-06-30 | 2018-01-04 | Zymergen Inc. | Methods for generating a glucose permease library and uses thereof |
| WO2018005655A2 (en) | 2016-06-30 | 2018-01-04 | Zymergen Inc. | Methods for generating a bacterial hemoglobin library and uses thereof |
| WO2018035387A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
| US11352647B2 (en) | 2016-08-17 | 2022-06-07 | The Broad Institute, Inc. | Crispr enzymes and systems |
| US9982267B2 (en) | 2016-10-12 | 2018-05-29 | Feldan Bio Inc. | Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same |
| US11629170B2 (en) | 2016-10-12 | 2023-04-18 | Feldan Bio Inc. | Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same |
| WO2018068135A1 (en) * | 2016-10-12 | 2018-04-19 | Feldan Bio Inc. | Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same |
| US11519009B2 (en) * | 2017-01-09 | 2022-12-06 | University Of Massachusetts | Complexes for gene deletion and editing |
| US11484603B2 (en) | 2017-03-31 | 2022-11-01 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods, systems, and compositions for inhibiting virulence of A/E family pathogens |
| WO2018183908A1 (en) | 2017-03-31 | 2018-10-04 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
| US20200071773A1 (en) | 2017-04-12 | 2020-03-05 | Massachusetts Eye And Ear Infirmary | Tumor signature for metastasis, compositions of matter methods of use thereof |
| US12226479B2 (en) | 2017-05-11 | 2025-02-18 | The General Hospital Corporation | Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof |
| US12297436B2 (en) | 2017-05-18 | 2025-05-13 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
| JP2020524490A (ja) | 2017-06-06 | 2020-08-20 | ザイマージェン インコーポレイテッド | Ｅｓｃｈｅｒｉｃｈｉａ Ｃｏｌｉを改良するためのＨＴＰゲノム操作プラットフォーム |
| JP7227162B2 (ja) | 2017-06-06 | 2023-02-21 | ザイマージェン インコーポレイテッド | 真菌株を改良するためのｈｔｐゲノム操作プラットフォーム |
| EP3638218A4 (en) | 2017-06-14 | 2021-06-09 | The Broad Institute, Inc. | COMPOSITIONS AND METHOD OF TARGETING COMPLEMENTING COMPONENT 3 FOR INHIBITION OF TUMOR GROWTH |
| JP7454494B2 (ja) | 2017-06-26 | 2024-03-22 | ザ・ブロード・インスティテュート・インコーポレイテッド | 標的化された核酸編集のためのｃｒｉｓｐｒ／ｃａｓ－アデニンデアミナーゼ系の組成物、系及び方法 |
| US12049643B2 (en) | 2017-07-14 | 2024-07-30 | The Broad Institute, Inc. | Methods and compositions for modulating cytotoxic lymphocyte activity |
| WO2019018440A1 (en) | 2017-07-17 | 2019-01-24 | The Broad Institute, Inc. | HUMAN COLON CELL ATLAS IN GOOD HEALTH AND WITH HEMORRHAGIC RECTO-COLITIS |
| CA3069542A1 (en) | 2017-08-04 | 2019-02-07 | Syngenta Participations Ag | Methods and compositions for targeted genomic insertion |
| KR102338449B1 (ko) | 2017-09-21 | 2021-12-10 | 더 브로드 인스티튜트, 인코퍼레이티드 | 표적화된 핵산 편집을 위한 시스템, 방법, 및 조성물 |
| WO2019071054A1 (en) | 2017-10-04 | 2019-04-11 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR MODIFYING THE FUNCTION AND STRUCTURE OF BUCKLES AND / OR CHROMATIN DOMAINS |
| WO2019094984A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods for determining spatial and temporal gene expression dynamics during adult neurogenesis in single cells |
| WO2019094955A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas |
| WO2019094983A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway |
| US11332736B2 (en) | 2017-12-07 | 2022-05-17 | The Broad Institute, Inc. | Methods and compositions for multiplexing single cell and single nuclei sequencing |
| CA3084572A1 (en) | 2017-12-18 | 2019-06-27 | Syngenta Participations Ag | Targeted insertion sites in the maize genome |
| US20230193242A1 (en) | 2017-12-22 | 2023-06-22 | The Broad Institute, Inc. | Cas12b systems, methods, and compositions for targeted dna base editing |
| US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
| WO2019210268A2 (en) | 2018-04-27 | 2019-10-31 | The Broad Institute, Inc. | Sequencing-based proteomics |
| US20210386829A1 (en) | 2018-05-04 | 2021-12-16 | The Broad Institute, Inc. | Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses |
| US12060388B2 (en) | 2018-05-25 | 2024-08-13 | Yale University | Cell-penetrating peptides and methods of use thereof |
| US20210371932A1 (en) | 2018-06-01 | 2021-12-02 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
| WO2019241315A1 (en) | 2018-06-12 | 2019-12-19 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| US12036240B2 (en) | 2018-06-14 | 2024-07-16 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
| EP3833761A1 (en) | 2018-08-07 | 2021-06-16 | The Broad Institute, Inc. | Novel cas12b enzymes and systems |
| WO2020041380A1 (en) | 2018-08-20 | 2020-02-27 | The Broad Institute, Inc. | Methods and compositions for optochemical control of crispr-cas9 |
| JP7344300B2 (ja) | 2018-09-18 | 2023-09-13 | ブイエヌブイ ニューコ インク． | Ａｒｃベースのカプシドおよびその使用 |
| CN109232719B (zh) * | 2018-09-21 | 2021-06-29 | 中国科学院理化技术研究所 | 一种pH响应的抗菌肽及其制备方法和应用 |
| US20220411783A1 (en) | 2018-10-12 | 2022-12-29 | The Broad Institute, Inc. | Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues |
| US20210379057A1 (en) | 2018-10-16 | 2021-12-09 | Massachusetts Institute Of Technology | Nutlin-3a for use in treating a mycobacterium tuberculosis infection |
| WO2020086742A1 (en) | 2018-10-24 | 2020-04-30 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| JP2022513408A (ja) | 2018-10-31 | 2022-02-07 | ザイマージェン インコーポレイテッド | Ｄｎａライブラリーの多重化決定論的アセンブリー |
| US12165743B2 (en) | 2018-11-09 | 2024-12-10 | The Broad Institute, Inc. | Compressed sensing for screening and tissue imaging |
| US12402610B2 (en) | 2018-11-09 | 2025-09-02 | The Broad Institute, Inc. | Methods and compositions for modulating innate lymphoid cell pathogenic effectors |
| WO2020123716A1 (en) | 2018-12-11 | 2020-06-18 | Obsidian Therapeutics, Inc. | Membrane bound il12 compositions and methods for tunable regulation |
| WO2020131862A1 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Crispr-associated transposase systems and methods of use thereof |
| US12264323B2 (en) | 2018-12-17 | 2025-04-01 | The Broad Institute, Inc. | CRISPR CPF1 direct repeat variants |
| WO2020130547A1 (ko) * | 2018-12-19 | 2020-06-25 | 한국화학연구원 | 인간 엘알알씨24 단백질 유래 세포막 투과 도메인 |
| KR102351041B1 (ko) * | 2018-12-19 | 2022-01-13 | 한국화학연구원 | 인간 lrrc24 단백질 유래 세포막 투과 도메인 |
| US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
| US12115212B2 (en) * | 2019-01-18 | 2024-10-15 | L & J Bio Co., Ltd. | Methods of decreasing amyloid beta (Aβ) plaque deposition and hyperphosphorylated tau plaque deposition in Alzheimer's disease using a cystatin C fusion protein |
| CN111471665B (zh) * | 2019-01-23 | 2023-07-04 | 上海科技大学 | 一种dna环化分子及其用途 |
| CN109734781B (zh) * | 2019-01-31 | 2021-12-14 | 东北农业大学 | 一种抗热带念珠菌肽及其制备方法和应用 |
| US20220135994A1 (en) | 2019-03-01 | 2022-05-05 | Syngenta Crop Protection Ag | Suppression of target gene expression through genome editing of native mirnas |
| US12215382B2 (en) | 2019-03-01 | 2025-02-04 | The General Hospital Corporation | Liver protective MARC variants and uses thereof |
| CA3129871A1 (en) | 2019-03-08 | 2020-09-17 | Zymergen Inc. | Iterative genome editing in microbes |
| US11053515B2 (en) | 2019-03-08 | 2021-07-06 | Zymergen Inc. | Pooled genome editing in microbes |
| KR20210149251A (ko) | 2019-03-08 | 2021-12-08 | 옵시디안 테라퓨틱스, 인크. | 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법 |
| CA3132817A1 (en) | 2019-03-08 | 2020-09-17 | Obsidian Therapeutics, Inc. | Cd40l compositions and methods for tunable regulation |
| US12419915B2 (en) | 2019-03-13 | 2025-09-23 | The Broad Institute, Inc. | Microglial progenitors for regeneration of functional microglia in the central nervous system and therapeutics uses thereof |
| WO2020191102A1 (en) | 2019-03-18 | 2020-09-24 | The Broad Institute, Inc. | Type vii crispr proteins and systems |
| RU2707542C1 (ru) | 2019-03-28 | 2019-11-27 | Федеральное бюджетное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ЦНИИ Эпидемиологии Роспотребнадзора) | Способ получения препарата рекомбинантной нуклеазы CAS, по существу, свободного от бактериальных эндотоксинов, полученный данным способом препарат и содержащий его набор для использования в системе CRISPR/Cas |
| CA3040645A1 (en) * | 2019-04-18 | 2020-10-18 | Feldan Bio Inc. | Peptide-based non-proteinaceous cargo delivery |
| US20220249701A1 (en) | 2019-05-14 | 2022-08-11 | The Broad Institute, Inc. | Compositions and methods for targeting multinucleated cells |
| US20220235340A1 (en) | 2019-05-20 | 2022-07-28 | The Broad Institute, Inc. | Novel crispr-cas systems and uses thereof |
| WO2020236972A2 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Non-class i multi-component nucleic acid targeting systems |
| WO2020243661A1 (en) | 2019-05-31 | 2020-12-03 | The Broad Institute, Inc. | Methods for treating metabolic disorders by targeting adcy5 |
| WO2020252404A1 (en) | 2019-06-12 | 2020-12-17 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| EP3983538A1 (en) | 2019-06-12 | 2022-04-20 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| KR20220039725A (ko) * | 2019-07-02 | 2022-03-29 | 트러스티즈 오브 터프츠 칼리지 | 작용제의 세포 및 조직으로의 전달을 위한 신규 펩티드, 조성물 및 방법 |
| US20230092895A1 (en) | 2019-08-30 | 2023-03-23 | Obsidian Therapeutics, Inc. | Tandem cd19 car-based compositions and methods for immunotherapy |
| WO2021041922A1 (en) | 2019-08-30 | 2021-03-04 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
| US20220348937A1 (en) | 2019-09-06 | 2022-11-03 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| US12297426B2 (en) | 2019-10-01 | 2025-05-13 | The Broad Institute, Inc. | DNA damage response signature guided rational design of CRISPR-based systems and therapies |
| US11981922B2 (en) | 2019-10-03 | 2024-05-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment |
| KR20220139319A (ko) | 2020-01-08 | 2022-10-14 | 옵시디안 테라퓨틱스, 인크. | 조정 가능한 전사의 조절을 위한 조성물 및 방법 |
| WO2021146641A1 (en) | 2020-01-17 | 2021-07-22 | The Broad Institute, Inc. | Small type ii-d cas proteins and methods of use thereof |
| CN111840334A (zh) * | 2020-07-21 | 2020-10-30 | 温州医科大学附属第一医院 | 普雷沃氏菌属在治疗或预防骨质疏松中的应用 |
| AU2021321586A1 (en) | 2020-08-07 | 2023-03-16 | Dana-Farber Cancer Institute, Inc. | Therapeutic targeting of phosphate dysregulation in cancer via the XPR1:KIDINS220 protein complex |
| WO2022044167A1 (ja) * | 2020-08-26 | 2022-03-03 | オリンパス株式会社 | 幹細胞の分化を評価するシステム、方法、及び、プログラム |
| WO2022077121A1 (en) * | 2020-10-18 | 2022-04-21 | Feldan Bio Inc. | Peptide-based transduction of non-anionic polynucleotide analogs for gene expression modulation |
| JP2023547405A (ja) * | 2020-10-22 | 2023-11-10 | フェルダン・バイオ・インコーポレーテッド | Ｃａｓ９－ＲＮＰ及び他の核タンパク質カーゴの形質導入のために適合された最小長のシャトル剤ペプチド及びそのバリアント |
| KR102803305B1 (ko) * | 2020-11-25 | 2025-05-07 | 연세대학교 산학협력단 | 트랜스-스플라이싱 아데노-연관 바이러스 벡터를 포함하는 프라임에디팅용 조성물 |
| CN115998894B (zh) * | 2021-10-21 | 2025-05-27 | 福州大学 | 一种硫属元素杂环化合物和胰岛素组装形成的团聚体及其制备方法和胰岛素口服制剂 |
| GB202116307D0 (en) | 2021-11-12 | 2021-12-29 | Syngenta Crop Protection Ag | Herbicide resistance |
| EP4437092A1 (en) | 2021-11-26 | 2024-10-02 | Epigenic Therapeutics Inc. | Method of modulating pcsk9 and uses thereof |
| CN115724990A (zh) * | 2022-07-19 | 2023-03-03 | 杭州纽龙生物科技有限公司 | 一种不影响与肝素结合能力的融合fgf1蛋白序列及对应的dna序列 |
| AR131755A1 (es) | 2023-02-03 | 2025-04-30 | Syngenta Crop Protection Ag | Plantas resistentes a herbicidas |
| CN121002047A (zh) | 2023-04-19 | 2025-11-21 | 先正达农作物保护股份公司 | 除草剂抗性植物 |
| CN116578092B (zh) * | 2023-05-29 | 2023-11-14 | 汕头大学 | 一种基于基因调控网络的智能体集群运动控制方法及系统 |
| WO2025019713A2 (en) | 2023-07-18 | 2025-01-23 | Beth Israel Deaconess Medical Center, Inc. | Protein-based delivery system |
| WO2025059533A1 (en) | 2023-09-13 | 2025-03-20 | The Broad Institute, Inc. | Crispr enzymes and systems |
| WO2025096916A1 (en) | 2023-11-03 | 2025-05-08 | The Broad Institute, Inc. | Multi-site editing in living cells |
| WO2025117544A1 (en) | 2023-11-29 | 2025-06-05 | The Broad Institute, Inc. | Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030104622A1 (en) | 1999-09-01 | 2003-06-05 | Robbins Paul D. | Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses |
| FR2849603B1 (fr) | 2003-01-07 | 2006-09-08 | Centre Nat Rech Scient | Composition pour le transport intracellulaire de macromolecules ou particules biologiques |
| CN1958606A (zh) * | 2005-10-31 | 2007-05-09 | 中国人民解放军军事医学科学院基础医学研究所 | 一种重组肝癌复合表位抗原,其制备方法及在制备肝癌特异免疫治疗药物中的应用 |
| EP1969000A2 (en) | 2005-12-06 | 2008-09-17 | Centre National de la Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| US7579318B2 (en) | 2005-12-06 | 2009-08-25 | Centre De La Recherche De La Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| US20100137202A1 (en) * | 2006-07-19 | 2010-06-03 | University Of Florida Research Foundation | Compositions for reprogramming a cell and uses therefor |
| US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
| WO2015038662A1 (en) * | 2013-09-10 | 2015-03-19 | The Texas A&M University System | Compositions and methods for the delivery of molecules into live cells |
| BR112016013201B1 (pt) | 2013-12-12 | 2023-01-31 | The Broad Institute, Inc. | Uso de uma composição compreendendo um sistema crispr-cas no tratamento de uma doença genética ocular |
| AU2016245347B2 (en) * | 2015-04-10 | 2021-01-28 | Feldan Bio Inc. | Polypeptide-based shuttle agents for improving the transduction efficiency of polypeptide cargos to the cytosol of target eukaryotic cells, uses thereof, methods and kits relating to same |
| WO2017049407A1 (en) | 2015-09-23 | 2017-03-30 | UNIVERSITé LAVAL | Modification of the dystrophin gene and uses thereof |
| WO2017175072A1 (en) | 2016-04-08 | 2017-10-12 | Feldan Bio Inc. | Peptide shuttle based gene disruption |
| WO2018053632A1 (en) | 2016-09-23 | 2018-03-29 | UNIVERSITé LAVAL | Methods of modifying the dystrophin gene and restoring dystrophin expression and uses thereof |
| US9982267B2 (en) | 2016-10-12 | 2018-05-29 | Feldan Bio Inc. | Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same |
| WO2018068135A1 (en) | 2016-10-12 | 2018-04-19 | Feldan Bio Inc. | Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same |
| US11629170B2 (en) * | 2016-10-12 | 2023-04-18 | Feldan Bio Inc. | Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same |
| CA3040645A1 (en) | 2019-04-18 | 2020-10-18 | Feldan Bio Inc. | Peptide-based non-proteinaceous cargo delivery |
-
2016
- 2016-04-08 AU AU2016245347A patent/AU2016245347B2/en active Active
- 2016-04-08 EP EP16775984.4A patent/EP3280739B1/en active Active
- 2016-04-08 CA CA2981716A patent/CA2981716C/en active Active
- 2016-04-08 US US15/094,365 patent/US9738687B2/en active Active
- 2016-04-08 CA CA3149413A patent/CA3149413C/en active Active
- 2016-04-08 ES ES16775984T patent/ES2864758T3/es active Active
- 2016-04-08 JP JP2018503698A patent/JP6956705B2/ja active Active
- 2016-04-08 WO PCT/CA2016/050403 patent/WO2016161516A1/en not_active Ceased
- 2016-04-08 SG SG11201708336YA patent/SG11201708336YA/en unknown
- 2016-04-08 KR KR1020217032040A patent/KR102697262B1/ko active Active
- 2016-04-08 CN CN201680033851.3A patent/CN107636017B/zh active Active
- 2016-04-08 KR KR1020177032555A patent/KR20170135957A/ko not_active Ceased
-
2017
- 2017-04-12 US US15/486,155 patent/US10633421B2/en active Active
- 2017-10-08 IL IL254919A patent/IL254919B/en unknown
-
2020
- 2020-02-21 US US16/797,867 patent/US12060387B2/en active Active
-
2021
- 2021-06-01 JP JP2021092230A patent/JP2021121224A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018512891A5 (enExample) | ||
| US12286632B2 (en) | Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same | |
| CA2981716C (en) | Polypeptide-based shuttle agents for improving the transduction efficiency of polypeptide cargos to the cytosol of target eukaryotic cells, uses thereof, methods and kits relating to same | |
| JP2019531316A5 (enExample) | ||
| Zhang et al. | Reprogramming of somatic cells via TAT-mediated protein transduction of recombinant factors | |
| CN106255699B (zh) | 细胞穿透肽和使用其输送生物活性物质的方法 | |
| Gagat et al. | Cell-penetrating peptides and their utility in genome function modifications | |
| US9982267B2 (en) | Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same | |
| US8420352B2 (en) | Protein delivery system to generate pluripotent stem (iPS) cells or tissue specific cells | |
| US20060229246A1 (en) | Peptide-enhanced transfections | |
| US20060222657A1 (en) | Polypeptide transduction and fusogenic peptides | |
| US11629170B2 (en) | Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same | |
| Pärn et al. | The antimicrobial and antiviral applications of cell-penetrating peptides | |
| KR101695792B1 (ko) | 신규 세포막 투과 펩티드 및 생리활성 물질 전달체로서의 그의 용도 | |
| Dey et al. | Thummer. Cell-Penetrating Peptides as a Tool to Deliver Biologically Active Recombinant Proteins to Generate Transgene-Free Induced Pluripotent Stem Cells | |
| JPWO2016052442A1 (ja) | 細胞質送達ペプチド | |
| Lyu et al. | Preparation of cell-permeable Cre recombinase by expressed protein ligation | |
| Patsch et al. | Conditional mutagenesis by cell-permeable proteins: potential, limitations and prospects | |
| ペプチドを利用した細胞内へのタンパク質 et al. | Peptide-Mediated Strategies for Intracellular Protein Delivery | |
| CN118184743A (zh) | 一种源于海洋动物的细胞膜穿透剂及其应用 | |
| Nakagawa | i, United States Patent (10) Patent No.: US 9.005967 B2 | |
| 游晧欣 | Development of novel systems promoting intracellular protein delivery |